Dealing with Global Safety Issues
Drug-induced torsade de pointes (TdP) is a potentially fatal iatrogenic entity. Its reporting rate in association with non-cardiac drugs increased exponentially from the early 1990s and was associated with an increasing number of new non-cardiac drugs whose proarrhythmic liability was not appreciated pre-marketing. This epidemic provoked a comprehensive global response from drug regulators, drug developers and academia, which resulted in stabilization of the reporting rate of TdP. This commentary reviews the chronology and nature of, and the reasons for, this response, examines its adequacy, and proposes future strategies for dealing with such iatrogenic epidemics more effectively. It is concluded that the response was piecemeal and lacked direction. No one entity was responsible, with the result that important contributions from regulators, industry and academia lacked coordination. While the process of dealing with QT crisis seemed to have worked reasonably well in this instance, it does not seem wise to expect the next crisis in drug development to be managed as well. Future crises will need better management and the challenge is to implement a system set up to respond globally and efficiently to a perceived drug-related hazard. In this regard, we discuss the roles of new tools the legislation has provided to the regulators and the value of an integrated expert assessment of all pre-approval data that may signal a potential safety issue in the postmarketing period. We also discuss the roles of other bodies such as the WHO Collaborating Centre for International Drug Monitoring, CIOMS and the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).
KeywordsCisapride Terfenadine Palonosetron Ranolazine Sertindole
The authors have not received any financial support for writing this commentary. Norman Stockbridge and Christine Garnett have no other affiliations or interests except at the FDA. Christine Garnett’s current affiliation is Certara, Cary, NC, USA. Joel Morganroth is the Chief Cardiac Consultant of eResearch Technology Inc. (ERT), Philadelphia, PA, USA, which provides cardiac safety services to the drug development community. Rashmi Shah was formerly a Senior Clinical Assessor at the Medicines and Healthcare products Regulatory Agency, London, UK, and the ICH E14 Topic Leader, representing the EU. Both Joel Morganroth and Rashmi Shah now provide expert consultancy services on the development of new drugs to a number of pharmaceutical companies.
The views and opinions expressed in this review are those of the authors and do not necessarily represent the views or opinions of their affiliate organizations, any of the regulatory authorities or their advisory committees.
- 8.Fung MC. Hsiao-hui Wu H, Kwong K, et al. Evaluation of the profile of patients with QT prolongation in spontaneous adverse event reporting over the past three decades – 1969–98. Pharmacoepidemiol Drug Saf. 2000;9(Suppl. 1):S24–5.Google Scholar
- 15.Therapeutic Goods Administration, Australia. Update on TGA decision to cancel prescription pain-killers. 21 Jun 2012. Available from URL: http://www.tga.gov.au/newsroom/media-2012-dextropropoxyphen-120621.htm. Accessed 20 Jul 2012.
- 16.European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Opinion following an article 31 referral (cisapride). EMEA/CPMP/24844/02. London, 7 Oct 2002. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Cisapride_31/WC500013943.pdf. Accessed 5 Apr 2012.
- 17.European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP/986/96. London, 17 Dec 1997. Available from URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs/cpmp.pdf. Accessed 5 Apr 2012.
- 19.Food and Drug Administration. Briefing document for NDA 20-644 (Serdolect) Psychopharmacologic Drugs Advisory Committee (PDAC) Meeting. 7 Apr 2009. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM161901.pdf. Accessed 20 Jul 2012.
- 20.European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Opinion of the Committee for Proprietary Medicinal Products pursuant to article 10 of Council Directive 75/319/EEC as amended. Mizollen (CPMP/1034/96-EN). London, 18 Dec 1996. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Mizollen_29/WC500011164.pdf. Accessed 5 Apr 2012.
- 21.European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of drug interactions. CPMP/EWP/560l95. London, 17 Dec 1997. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002966.pdf. Accessed 5 Apr 2012.
- 22.Lessons from cisapride [editorial]. CMAJ 2001; 164: 1269.Google Scholar
- 24.Specification for annotated electrocardiographic waveform data in electronic format: request for comments. Fed Register 2003; 68: 22719.Google Scholar
- 25.Food and Drug Administration. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Preliminary concept paper for discussion purposes only (Nov 15, 2002). Available from URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs%5Cprelim.pdf. Accessed 23 Jul 2012.
- 26.International Conference on Harmonization. Organization of ICH: Global Cooperation Group. Available from URL: http://www.ich.org/about/organisation-of-ich/coopgroup.html. Accessed 20 Jul 2012.
- 27.European Agency for the Evaluation of Medicinal Products, Committee for Medicinal Products for Human Use. ICH note for guidance on the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (ICH S7B). CHMP/ICH/423/02. London, Nov 2005. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002841.pdf. Accessed 5 Apr 2012.
- 28.European Agency for the Evaluation of Medicinal Products, Committee for Medicinal Products for Human Use. ICH note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (ICH E14). CHMP/ICH/2/04). London, Nov 2005. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002879.pdf. Accessed 5 Apr 2012.
- 29.European Medicines Agency, Committee for Medicinal Products for Human Use. ICH Topic E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: questions and answers. EMEA/CHMP/ICH/310133/2008. London, Jun 2008. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002878.pdf. Accessed 5 Apr 2012.
- 56.Food and Drug Administration. Cardiac Safety Research Consortium (CSRC). Available from URL: http://www.fda.gov/AboutFDA/PartnershipsCollaborations/PublicPrivatePartnershipProgram/ucm231121.htm. Accessed 5 Apr 2012.
- 61.FDA/PhRMA Task Force to assess QT risk by preclinical markers. Pink Sheet 1999; 61: 15.Google Scholar
- 64.Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32–45.PubMedCrossRefGoogle Scholar
- 66.Dmitrienko A, Smith BP. Analysis of the QT interval in clinical trials. Drug Inf J. 2002;36:269–79.Google Scholar
- 67.Patterson SD, Agin M, Anziano R, et al. Investigating drug-induced QT and QTc prolongation in the clinic: a review of statistical design and analysis considerations. Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team. Drug Inf J. 2005;39:243–66.Google Scholar
- 76.CIOMS. Practical aspects of signal detection in pharmacovigilance. Report of CIOMS Working Group VIII. 2010. ISBN 92 9036 082 8. Available from URL: http://www.cioms.ch/publications/blurbs/WGVIIIblurbDRAFT.pdf. Accessed 25 Apr 2012.
- 77.Health Level Seven International. Available from URL: www.hl7.org. Accessed 3 Jan 2013.
- 78.Cardiac Safety Research Consortium. Available from URL: www.cardiac-safety.org. Accessed 3 Jan 2013.
- 80.Metrics Champion Consortium. Available from URL: www.metricschampion.org. Accessed 3 Jan 2013.
- 81.The WHO Uppsala Monitoring Centre. Available from URL: www.who-umc.org. Accessed 3 Jan 2013.
- 82.CIOMS. Available from URL: www.cioms.ch. Accessed 3 Jan 2013.
- 83.International Conference on Harmonization. Available from URL: www.ich.org. Accessed 3 Jan 2013.